New study aims to unlock secrets of systemic sclerosis through patient samples
NCT ID NCT05532865
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is gathering blood, stool, and skin samples from 100 adults with systemic sclerosis to learn more about the disease. Researchers will also track health information like skin thickness, lung function, and quality of life over time. The goal is to build a biobank for future research, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help researchers better understand how systemic sclerosis progresses and identify factors that influence the disease.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly benefit participants and may not lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2022
- Expected to finish
-
Oct 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Major patient with systemic sclerosis defined according to the EULAR 2013 criteria
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Major patient with systemic sclerosis defined according to the EULAR 2013 criteria (see Appendix 1) * Patient evaluated within the framework of the reference center for rare autoimmune diseases of the CHU of Brest. * Patient affiliated to the social security system * Patient having signed a written informed consent. Exclusion Criteria: * Minor * Patient under legal protection (guardianship, curatorship) * Refusal to participate * Patient unable to consent * Pregnant or breastfeeding woman * Hemoglobin (Hb) level \< 7g/dl
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Systemic sclerosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHRU de Brest
RECRUITINGBrest, 29200, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Inhaled xenon gas could reveal hidden lung vessel disease without catheter
- Can a single drug tame multiple autoimmune diseases?
- Immune clues in the blood may foretell heart trouble
- Blood particles may reveal hidden clues to scleroderma complications
- Could a simple injection dissolve painful calcium lumps in rare diseases?
- Finger injections aim to loosen stiff hands in scleroderma